Virbac confirms outlook as Supercharge platforms drive profit growth

Virbac SA

17/09/2026 17:30

Adds metrics in bullets 1 and 3, adds CEO quote in para 2
Sept 17 (Reuters) - French animal health company Virbac VIRB.PA reported higher half-year core profit on Thursday with a recurring operating profit, excluding amortization of assets due to acquisitions, rising 6.8% to 144.2 million euros ($165.50 million), compared with 135.0 million euros a year earlier.
     Virbac confirmed its 2026 outlook at the upper end of its target range (5.5%-7.5%), with CEO Paul Martingell citing the "scaling power" of the group's Supercharge platforms and the successful integration of Thyronorm. 
Revenue reached 768 million euros, up 7.4% at constant exchange rates and scope, driven by companion animal growth of 10.0% and farm animal growth of 6.7%.
"This performance reflects the scaling power of our 'Supercharge' platforms" said CEO Paul Martingell. 
Virbac said its "Supercharge" platforms grew about 12% excluding Thyronorm, while the acquisition contributed an additional 3.7 percentage points to platform growth and strengthened its endocrinology business.
Virbac acquired feline hyperthyroidism drug Thyronorm, sold as Felanorm in the US, from Norbrook in December 2025. 
The company also highlighted two specialty-asset deals, Porus-One and Vetcare, as part of its strategy to add high-margin complementary products.
($1 = 0.8713 euros)

 (Reporting by Margaux Perrin and Jérôme Terroy in Gdansk; Editing by Matt Scuffham)
 ((Margaux.Perrin@thomsonreuters.com, Jerome.Terroy@thomsonreuters.com))